Atlas Trials

A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL

Clinical trial NCT05178836 · UNKNOWN

Trial details

NCT number
NCT05178836
Sponsor
Shandong New Time Pharmaceutical Co., LTD
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
RR DLBCL; PD-1; CD20
Start date
2022-01-01
Primary completion
2023-12-31
Enrollment
62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.